Sanofi
SNYHealthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was 7.05% in Q3 FY26, the highest of these four quarters.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | 10.9% | 0.0% | 5.9% | 0.0% |
| ROIC | 6.6% | 6.1% | 6.6% | 7.0% |
Debt
Net debt is 2.76× a year’s EBITDA. Debt is 0.24× equity, against 0.31× in Q2 FY26.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Debt / equity | 0.3× | 0.2× | 0.3× | 0.2× |
| Net debt / EBITDA | 11.0× | 6.1× | 7.1× | 2.8× |
Cash cycle, in days
Customers pay in 2 days, inventory is held 670 days and suppliers are paid in 657. Cash is tied up for 15 days between paying for goods and being paid.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Cash cycle | 149 | 26 | 177 | 15 |
| Days to pay suppliers | 206 | 630 | 196 | 657 |
| Days to be paid | 69 | 4 | 69 | 2 |
Per share, from Q4 FY25
Since Q4 FY25, per share: free cash flow has grown 30.0%; revenue has grown 13.7%; book value has grown 5.67%.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Free cash flow | 1.0× | 0.0× | 0.8× | 1.3× |
| Revenue | 1.0× | 1.1× | 1.1× | 1.1× |
| Book value | 1.0× | 1.1× | 1.0× | 1.1× |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 6 | — | 7 |
+8 more TTM periods Free account |
| 0.00% | 5.87% | 0.00% | 10.94% | ||
| 3.24% | 3.21% | 6.06% | 6.16% | ||
ROIC |
7.05% | 6.58% | 6.12% | 6.57% | |
Return on Tangible Assets |
30.43% | 40.46% | 72.55% | 61.72% | |
Average Days of Receivables |
2.32 | 68.60 | 3.75 | 68.81 | |
Free Cash Flow per Share |
9.91 | 6.08 | 0.00 | 7.62 | |
Free Cash Flow |
23,792.82 | 14,542.46 | — | 18,607.12 | |
Capital Expenditures |
— | (7,054.14) | — | (7,417.62) | |
| Other line items | |||||
Cash ROIC |
21.28% | 12.82% | 0.00% | 16.79% | |
Accounts Receivable Turnover |
123.61 | 5.69 | 105.97 | 5.55 | |
Accounts Payable Turnover |
0.58 | 1.90 | 0.62 | 1.79 | |
Inventory Turnover |
0.55 | 1.30 | 0.61 | 1.36 | |
Average Days of Payables |
657.21 | 195.73 | 630.21 | 205.90 | |
Days of Inventory on Hand |
669.80 | 304.59 | 652.28 | 285.70 | |
Tax Rate |
(0.28) | (0.22) | (0.17) | (0.17) | |
Research and Development Expense of Revenue |
15.95% | 16.58% | 16.43% | 16.79% | |
Selling, General and Administrative Expense of Revenue |
19.35% | 20.11% | 20.39% | 20.43% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
14.25 | 13.21 | 15.83 | 15.43 | |
Operating CF/Net income |
4.87 | 4.61 | 0.00 | 2.94 | |
Depreciation/Fixed assets |
0.00 | 1.30 | 0.00 | 1.22 | |
Capex/Depreciation |
— | (0.45) | — | (0.53) | |
Revenue per Share |
24.62 | 23.80 | 22.77 | 21.65 | |
Operating CF per Share |
9.91 | 9.02 | 0.00 | 10.66 | |
Capex per Share |
0.00 | (2.95) | 0.00 | (3.04) | |
Capex to Sales |
0.00 | 0.12 | 0.00 | 0.14 |